RaySearch Deepens Collaboration with P-Cure

RaySearch Laboratories AB (publ) is pleased to announce its expanded collaboration with P-Cure, aiming at enhancing the workflow efficiency of P-Cure’s proton therapy system through integration with RaySearch’s systems RayStation®* and RayCare®*.

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

The partnership is an organic continuation of the existing relationship between the companies that has already resulted in integration of RayStation in a study conducted at the P-Cure clinical development center, operated clinically by Hadassah Medical Center.

The partnership will enable users of the P-Cure proton therapy system to also utilize the automation and workflow support provided by RayCare, as well as the features for adaptive radiation therapy in the RaySearch systems.

Dr. Michael Marash, CEO of P-Cure, says: “Our partnership with RaySearch, the world leader in treatment planning, will play an important role in our pioneering efforts to bring the benefits of proton therapy to help a far larger world-wide patient body. I am happy that we have now taken our partnership to the next level and I believe our technologies have great potential together.”

Johan Löf, founder and CEO, RaySearch, says: “We are proud to work with a company that is ushering in a new era of proton therapy. P-Cure is a pioneer in the development of upright radiation therapy, and the ability to provide a proton system in a regular linac room has great potential to expand proton therapy.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version